NCT02843399View on ClinicalTrials.gov

Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy

CompletedOBSERVATIONAL

Enrollment

15,498

Participants

Timeline

Start Date

August 15, 2016

Primary Completion Date

December 15, 2016

Study Completion Date

December 15, 2016

Conditions

Diabetes Mellitus Type 2

Trial Locations (1)

Unknown

Research site, Wilmington

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Truven health

UNKNOWN

lead

AstraZeneca

INDUSTRY